Clinical Trial Update: Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing efficacy, pharmacodynamics, safety, and immunogenicity of Bmab 1000 versus Prolia (denosumab) in postmenopausal women with osteoporosis;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Bmab 1000
• Prolia (denosumab)

Snippet

Sponsor: Biocon Biologics UK Ltd | Conditions: Postmenopausal Women With Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2025-08-19